Medicine and Dentistry
Empagliflozin
100%
Congestive Heart Failure
100%
Placebo
48%
Ejection Fraction
42%
Randomized Controlled Trial
28%
Growth Differentiation Factor 15
25%
Neprilysin
25%
Biological Marker
25%
Angiotensin Receptor
25%
Enkephalinase Inhibitor
21%
Sodium Glucose Cotransporter 2 Inhibitor
17%
Heart Failure with Reduced Ejection Fraction
11%
Heart Left Ventricle Ejection Fraction
9%
End-Diastolic Volume
8%
Diabetes
8%
C Reactive Protein
6%
Troponin T
6%
Accelerometer
6%
Stress Echocardiography
6%
End-Systolic Volume
6%
Adipose Tissue
5%
Sodium Glucose Cotransporter 2
5%
Treatment Effect
5%
Pharmacology, Toxicology and Pharmaceutical Science
Empagliflozin
100%
Congestive Heart Failure
100%
Placebo
48%
Randomized Controlled Trial
28%
Biological Marker
25%
Growth Differentiation Factor 15
25%
Membrane Metalloendopeptidase
25%
Angiotensin Receptor
25%
Enkephalinase Inhibitor
21%
Sodium Glucose Cotransporter 2 Inhibitor
17%
Heart Failure with Reduced Ejection Fraction
11%
C Reactive Protein
6%
Troponin T
6%
Sodium Glucose Cotransporter 2
5%
Non Insulin Dependent Diabetes Mellitus
5%
